Explore the words cloud of the Lung EpiCheck project. It provides you a very rough idea of what is the project "Lung EpiCheck" about.
The following table provides information about the project.
|Coordinator Country||Israel [IL]|
|Total cost||3˙509˙375 €|
|EC max contribution||2˙456˙562 € (70%)|
1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
|Duration (year-month-day)||from 2018-11-01 to 2020-10-31|
Take a look of project's partnership.
Nucleix has developed a highly innovative process for cancer diagnostics. The company plans to introduce Innovative Technique for Lung Cancer Diagnostics via identification of changes in DNA Methylation in Blood Samples. The company has already introduced successfully the Bladder EpiCheck and gained experience in the process of: clinical validation, regulatory approvals and commercialization of bladder cancer diagnostic of cancer via identification of changes in DNA Methylation. Nucleix’s current technology of lung cancer detection in blood samples – Lung EpiCheck - was developed using the same technology and team which has successfully developed Bladder EpiCheck. Nucleix breakthrough innovations are in the area of cancer detection using a unique combination of a best-in-class biochemical tool, combined with advanced big-data bioinformatics analysis. Lung EpiCheck is a high-potential innovation idea and though having some risk in the process of market adaptation it creates a very high commercial opportunity for Nucleix for growth and a successful mature enterprise At present, lung cancer is usually detected at late stages, where survival rates are very low – about 15%. The reason for this is that lung cancer patients are mostly asymptomatic in early stages. Detecting lung cancer in early stages significantly improves survival rates to 50% to 80%, thus a good tool for lung cancer detection has huge potential. The current high clinical results of Lung EpiCheck and the meetings with European potential customers (such as leading medical centers and lab chains) shows that the project proposed methodology and the expected performance is very promising to potential customers and market leaders. These potential customers have also confirmed company’s assumption about pricing that provides proper value for money. Nucleix’s technology is expected to create a huge value proposition to patients, physicians and payers identified as the main stakeholders
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "LUNG EPICHECK" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (firstname.lastname@example.org) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "LUNG EPICHECK" are provided by the European Opendata Portal: CORDIS opendata.
First in the world ecological and sustainable cream for wound care, based on microalgaprasinococcus capsulatusRead More
First anti-fraud plataform for the registration and certification of diplomas and academic certificates based in blockchainRead More
FAST-RESPONSIVE and LONG-LASTING TRANSPARENT PHOTOCHROMIC FILMSRead More